ADMS Adamas Pharmaceuticals, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

ADMS [NASD]

Adamas Pharmaceuticals, Inc.

Healthcare | Drug Manufacturers - Specialty & Generic | USA

statements

Index	-	P/E	-	EPS (ttm)	-3.32	Insider Own	1.90%	Shs Outstand	28.03M	Perf Week	5.08%
Market Cap	71.20M	Forward P/E	-	EPS next Y	-1.35	Insider Trans	-0.25%	Shs Float	27.41M	Perf Month	-7.88%
Income	-92.20M	PEG	-	EPS next Q	-0.61	Inst Own	77.30%	Short Float	3.40%	Perf Quarter	-10.03%
Sales	57.50M	P/S	1.24	EPS this Y	22.00%	Inst Trans	1.08%	Short Ratio	2.03	Perf Half Y	-51.53%
Book/sh	-0.57	P/B	-	EPS next Y	38.10%	ROA	-53.70%	Target Price	-	Perf Year	-55.09%
Cash/sh	4.35	P/C	0.62	EPS next 5Y	46.30%	ROE	-806.50%	52W Range	1.90 - 7.78	Perf YTD	-29.02%
Dividend	-	P/FCF	-	EPS past 5Y	-52.90%	ROI	-72.70%	52W High	-64.97%	Beta	1.81
Dividend %	-	Quick Ratio	5.40	Sales past 5Y	-0.40%	Gross Margin	95.40%	52W Low	43.42%	ATR	0.19
Employees	136	Current Ratio	5.60	Sales Q/Q	23.90%	Oper. Margin	-	RSI (14)	52.06	Volatility	5.56% 6.73%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	45.00%	Profit Margin	-	Rel Volume	0.21	Prev Close	2.69
Shortable	Yes	LT Debt/Eq	-	Earnings	May 07 AMC	Payout	-	Avg Volume	459.62K	Price	2.72
Recom	2.20	SMA20	2.08%	SMA50	-3.20%	SMA200	-33.02%	Volume	51,478	Change	1.30%

Dec-18-19

Reiterated

H.C. Wainwright

Buy

$30 → $10

Sep-30-19

Downgrade

BofA/Merrill

Neutral → Underperform

$9 → $5

Sep-09-19

Initiated

Cantor Fitzgerald

Neutral

Mar-05-19

Downgrade

Mizuho

Neutral → Underperform

$11 → $5

Nov-05-18

Downgrade

Mizuho

Buy → Neutral

Oct-05-18

Downgrade

BofA/Merrill

Buy → Neutral

Jul-16-18

Initiated

H.C. Wainwright

Buy

$45

Apr-04-18

Initiated

Leerink Partners

Outperform

$31

Mar-27-18

Initiated

BofA/Merrill

Buy

$39

Nov-29-17

Initiated

Northland Capital

Outperform

$70

Nov-08-17

Reiterated

Noble Financial

Buy

$33 → $48

Oct-30-17

Initiated

Evercore ISI

Outperform

$85

Sep-29-17

Resumed

Noble Financial

Buy

$33

Sep-19-17

Reiterated

Mizuho

Buy

$26 → $48

Aug-25-17

Reiterated

JMP Securities

Mkt Outperform

$29 → $33

Sep-08-16

Reiterated

Mizuho

Buy

$22 → $26

Jun-17-16

Initiated

Noble Financial

Buy

$25

Jun-16-16

Upgrade

Mizuho

Neutral → Buy

$22

May-12-16

Reiterated

Mizuho

Neutral

$17 → $16

Apr-28-16

Reiterated

Mizuho

Neutral

$14 → $17

Jul-10-20 04:05PM	Adamas Announces New Employment Inducement Grant GlobeNewswire +6.32%
Jun-18-20 08:34AM	The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions Benzinga -6.99%
Jun-17-20 04:01PM	Adamas provides program update for ADS-5102 for multiple sclerosis patients with walking impairment GlobeNewswire
Jun-05-20 07:34AM	The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets $400M Bid Benzinga +12.88%
Jun-04-20 04:30PM	Adamas announces FDA filing acceptance of sNDA to modify the indication statement for GOCOVRI® to include treatment for Parkinsons disease patients receiving levodopa and experiencing OFF episodes GlobeNewswire
Jun-03-20 04:01PM	Adamas to Present at Upcoming William Blair Conference GlobeNewswire
May-20-20 10:04PM	Edited Transcript of ADMS earnings conference call or presentation 7-May-20 9:00pm GMT Thomson Reuters StreetEvents
May-13-20 09:15AM	Adamas announces issuance of new U.S. patent for GOCOVRI in Parkinsons disease - expands coverage with reduction of OFF time and increased good ON time GlobeNewswire -7.48%
May-08-20 06:46PM	Adamas Announces New Employment Inducement Grant GlobeNewswire -13.29%
May-07-20 04:03PM	Adamas Reports First Quarter 2020 Financial Results GlobeNewswire
Apr-30-20 12:34PM	Adamas Pharmaceuticals (ADMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release Zacks -5.00%
Apr-28-20 12:00PM	All You Need to Know About Adamas (ADMS) Rating Upgrade to Buy Zacks
Apr-27-20 04:03PM	Adamas to Announce First Quarter 2020 Financial Results and Host Conference Call on May 7, 2020 GlobeNewswire
Apr-10-20 04:06PM	Adamas Announces New Employment Inducement Grant GlobeNewswire
Mar-23-20 03:15PM	Adamas Pharmaceuticals Stock Kehoe Law Firm, P.C. Investigating Breach of Fiduciary Duty Claims on Behalf of ADMS Investors ADMS Shareholders Encouraged to Contact Kehoe Law Firm, P.C. GlobeNewswire +7.05%
Mar-20-20 10:44AM	Generic Drugs Industry's Prospects Uncertain Amid Coronavirus Zacks
Mar-19-20 04:46PM	Adamas Pharmaceuticals Stock - Kehoe Law Firm, P.C. Investigating Breach of Fiduciary Duty Claims on Behalf of ADMS Investors - ADMS Shareholders Encouraged to Contact Kehoe Law Firm, P.C. PR Newswire +21.61%
Mar-10-20 02:26PM	Edited Transcript of ADMS earnings conference call or presentation 25-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Mar-06-20 04:39PM	Adamas Announces New Employment Inducement Grant GlobeNewswire
Feb-28-20 06:26AM	Earnings Update: Here's Why Analysts Just Lifted Their Adamas Pharmaceuticals, Inc. Price Target To US$12.69 Simply Wall St.
Feb-25-20 05:35PM	Adamas Pharmaceuticals (ADMS) Reports Q4 Loss, Tops Revenue Estimates Zacks -9.14%
04:03PM	Adamas Reports Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire
Feb-24-20 09:02AM	Cronos (CRON) to Report Q4 Earnings: What's in the Cards? Zacks -9.33%
Feb-20-20 04:01PM	Adamas to Present at Upcoming Healthcare Conferences GlobeNewswire
Feb-19-20 04:02PM	Adamas to Announce Fourth Quarter 2019 Financial Results and Host Conference Call on February 25, 2020 GlobeNewswire
Feb-13-20 09:00AM	Adamas To Present Analysis of Clinical Trials on GOCOVRI® Treatment at the 3rd Pan American Parkinsons Disease and Movement Disorders Congress GlobeNewswire
Feb-12-20 09:18AM	The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data Benzinga +6.15%
Feb-11-20 04:15PM	Adamas Announces Publication of the Two-Year Phase 3 Open-Label EASE LID 2 Trial of GOCOVRI® for Dyskinesia in Patients with Parkinsons Disease GlobeNewswire
Feb-10-20 10:50AM	SHAREHOLDER ALERT: ADMS GDOT BYND: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
10:00AM	ADMS FINAL DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10th Deadline in Securities Class Action ADMS GlobeNewswire
09:57AM	FINAL DEADLINE ALERT - Adamas Pharmaceuticals, Inc. (ADMS) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: February 10, 2020 ACCESSWIRE
Feb-09-20 10:25AM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADMS, OPRA and PTLA ACCESSWIRE
Feb-08-20 10:30AM	ADMS FINAL DEADLINE: ROSEN, INVESTOR COUNSEL, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10 Deadline in Securities Class Action - ADMS ACCESSWIRE
Feb-07-20 01:30PM	CLASS ACTION UPDATE for ADMS, GDOT and PTLA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
10:00AM	DEADLINE ALERT - Adamas Pharmaceuticals, Inc. (ADMS) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: February 10, 2020 GlobeNewswire
Feb-06-20 05:40PM	CLASS ACTION UPDATE for ADMS, SSL and BZUN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
01:30PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS ACCESSWIRE
Feb-05-20 06:00PM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADMS, GDOT and FSCT ACCESSWIRE
03:15PM	5-Day Deadline Alert: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
01:40PM	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ADMS, XYF and PTLA ACCESSWIRE
11:26AM	ADAMAS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Adamas Pharmaceuticals, Inc.s January 24, 2018 Secondary Public Offering To Contact The Firm GlobeNewswire
10:52AM	CLASS ACTION UPDATE for ADMS, FSCT and BYND: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
09:56AM	DEADLINE ALERT - Adamas Pharmaceuticals, Inc. (ADMS) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: February 10, 2020 ACCESSWIRE
Feb-04-20 08:40PM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADMS, FSCT and PTLA ACCESSWIRE
08:05PM	6-Day Deadline Alert: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
01:41PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS GlobeNewswire
12:30PM	SHAREHOLDER ALERT: ADMS PTLA GERN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
12:00PM	Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. GlobeNewswire
11:12AM	INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in Adamas Pharmaceuticals, and Exelon Corporation of Filing Deadlines GlobeNewswire
10:12AM	ADMS INVESTOR ALERT: Bernstein Liebhard LLP Reminds Investors of a Filing Deadline in a Securities Class Action Against Adamas Pharmaceuticals, Inc ACCESSWIRE
Feb-03-20 03:45PM	SHAREHOLDER ALERT: ADMS GDOT PTLA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
01:45PM	NOTICE FROM FIRM THAT FILED THE LAWSUIT: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
01:00PM	DEADLINE ALERT for XYF, BZUN, ADMS, MHK: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
10:45AM	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ADMS, GDOT and XYF ACCESSWIRE
10:11AM	ADMS INVESTOR DEADLINE IN 7 DAYS: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Against Adamas Pharmaceuticals, Inc. Business Wire
Feb-01-20 02:17PM	ADMS INVESTOR ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Against Adamas Pharmaceuticals, Inc. ACCESSWIRE
02:00PM	ADMS FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10th Deadline in Securities Class Action ADMS GlobeNewswire
Jan-31-20 04:35PM	SHAREHOLDER ALERT: ADMS MMSI OPRA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
02:22PM	INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in Adamas Pharmaceuticals, and Exelon Corporation of Filing Deadlines GlobeNewswire
01:55PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS ACCESSWIRE
01:37PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS GlobeNewswire
01:15PM	CLASS ACTION UPDATE for ADMS, FCAU and GERN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
11:16AM	ADAMAS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Adamas Pharmaceuticals, Inc. (ADMS) To Contact The Firm Business Wire
10:20AM	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ADMS, MMSI and FCAU ACCESSWIRE
09:57AM	INVESTOR ALERT: ADMS and BZUN: Bronstein, Gewirtz & Grossman LLC Alerts Shareholders With Losses Exceeding $100K of Class Action Deadlines ACCESSWIRE
Jan-30-20 01:10PM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADMS, EXC and QD ACCESSWIRE
Jan-29-20 04:40PM	ALERT FROM FIRM THAT FILED THE LAWSUIT: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
01:30PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS ACCESSWIRE
01:19PM	ADAMAS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Adamas Pharmaceuticals, Inc. (ADMS) To Contact The Firm GlobeNewswire
11:30AM	Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. GlobeNewswire
09:00AM	Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against X Financial, Baozun, Adamas Pharmaceuticals, and Cintas and Encourages Investors to Contact the Firm GlobeNewswire
Jan-28-20 08:55PM	ADMS SHAREHOLDER ALERT: ROSEN, A LEADING FIRM, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10 Deadline in Securities Class Action - ADMS ACCESSWIRE
03:10PM	NOTICE FROM FIRM THAT FILED THE LAWSUIT: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
12:30PM	CLASS ACTION UPDATE for ADMS, GDOT and QD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
12:13PM	ADMS LOSSES ALERT: Bernstein Liebhard LLP Encourages Investors With Losses in ADMS Exceeding 20K to Contact the Firm and Reminds Investors of a Filing Deadline in a Securities Class Action Against Adamas Pharmaceuticals, Inc ACCESSWIRE
11:47AM	ADAMAS SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Adamas Pharmaceuticals, Inc. (ADMS) To Contact The Firm Newsfile
10:00AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS GlobeNewswire
Jan-27-20 06:55PM	SHAREHOLDER ALERT: ADMS HEXO FCAU: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
05:06PM	INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in Adamas Pharmaceuticals, and Exelon Corporation of Filing Deadlines GlobeNewswire
01:40PM	CLASS ACTION UPDATE for ADMS, QD and GERN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
11:15AM	ALERT FROM FIRM THAT FILED THE LAWSUIT: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
11:00AM	DEADLINE ALERT for XYF, BZUN, ADMS, MHK: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
10:45AM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADMS, QD and GERN ACCESSWIRE
09:35AM	ADAMAS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Adamas Pharmaceuticals, Inc. (ADMS) To Contact The Firm Newsfile
Jan-26-20 07:55AM	Does Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Have A Particularly Volatile Share Price? Simply Wall St.
Jan-24-20 05:15PM	SHAREHOLDER ALERT: ADMS REAL EXC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE -9.32%
03:12PM	ADMS INVESTOR ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Against Adamas Pharmaceuticals, Inc. ACCESSWIRE
10:25AM	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ADMS, REAL and BZUN ACCESSWIRE
10:00AM	INVESTOR ALERT: ADMS and BZUN: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders With Losses Exceeding $100K of Class Action Deadlines GlobeNewswire
Jan-23-20 05:44PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS GlobeNewswire
11:35AM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ADMS, MMSI and PTLA ACCESSWIRE
11:00AM	Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. GlobeNewswire
Jan-22-20 02:50PM	SHAREHOLDER ALERT: ADMS XYF BZUN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
02:00PM	Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Baozun, Adamas Pharmaceuticals, Cintas, and Correvio Pharma and Encourages Investors to Contact the Firm GlobeNewswire
01:19PM	INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in Adamas Pharmaceuticals, and Exelon Corporation of Filing Deadlines GlobeNewswire
10:50AM	CLASS ACTION UPDATE for ADMS, BAX and MHK: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
09:07AM	ADMS INVESTOR ALERT: Bernstein Liebhard LLP Encourages Investors With Losses in ADMS Exceeding 20K to Contact the Firm and Reminds Investors of a Filing Deadline in a Securities Class Action Against Adamas Pharmaceuticals, Inc ACCESSWIRE
Jan-21-20 07:05PM	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ADMS, BAX and MMSI ACCESSWIRE
05:50PM	ADMS INVESTOR NOTICE: ROSEN, A TOP RANKED LAW FIRM, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10th Deadline in Securities Class Action ADMS GlobeNewswire
11:55AM	CLASS ACTION UPDATE for ADMS, GRUB and XYF: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Prentiss Christopher B	Chief Financial Officer	Jan 21	Sale	5.92	1,269	7,512	70,940	Jan 23 05:33 PM
MERRIWEATHER ALFRED G	Chief Financial Officer	Sep 20	Sale	6.91	1,584	10,945	48,019	Sep 23 04:19 PM
MAHONEY DAVID L	Director	Sep 17	Option Exercise	1.76	33,332	58,498	57,153	Sep 18 04:38 PM
Prentiss Christopher B	Chief Accounting Officer	Jul 22	Sale	6.00	1,082	6,492	47,209	Jul 23 06:06 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience